Automate Your Wheel Strategy on REVBW
With Tiblio's Option Bot, you can configure your own wheel strategy including REVBW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol REVBW
- Rev/Share 0.0
- Book/Share 2.9658
- PB 0.2765
- Debt/Equity 0.0
- CurrentRatio 3.6052
- ROIC -2.8354
- MktCap 1664435.0
- FreeCF/Share -23.9667
- PFCF -0.0715
- PE -0.0553
- Debt/Assets 0.0
- DivYield 0
- ROE -0.0122
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Revelation Biosciences, Inc. (REVBW)
- IPO Date
- Website https://www.revbiosciences.com
- Industry Biotechnology
- CEO James M. Rolke
- Employees 8
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.